欧洲未活跃的市场规模、工业范围、预测

Europe Underactive Bladder Market

市场规模（十亿美元）

CAGR : 4.50 %

USD 1.15 Billion USD 1.63 Billion 2025 2033

Forecast Period	2026 –2033
Market Size (Base Year)	USD 1.15 Billion
Market Size (Forecast Year)	USD 1.63 Billion
CAGR	4.50 %
Major Markets Players	Astellas Pharma Inc. (日本) 波士顿科学公司(美国) Coloplast Corp (丹麦) Convatec Group PLC (英国) Cook (美国).

欧洲低活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性活性 2033年工业趋势和预测

欧洲未活跃的刀锋市场概况

欧洲活动不足的膀胱市场的价值2025年15亿美元预计将达到到2033年达到16.3亿美元,生长在一个2026年至2033年的CAGR为4.5%市场正在稳步增长,其动力是老年人口中泌尿道滞留障碍的发病率不断上升,对尿道功能障碍的认识得到提高,泌尿道诊断和治疗技术得到提高。

神经系统疾病、糖尿病和与年龄有关的膀胱功能失调在欧洲国家造成的负担日益加重,加上获得专门的泌尿科护理的机会增加,正在鼓励保健提供者采用先进的治疗和诊断解决办法。此外,增加对最低侵入性治疗、导管技术、神经调节疗法和康复方案的投资正在支持扩大市场。有利的保健基础设施、不断增加的保健支出以及正在进行的膀胱功能失调管理临床研究,都进一步促进了在全区域采用创新的低活性膀胱治疗解决方案

主要市场趋势和见解

2025年,德国在欧洲的膀胱不活跃市场占据了主导地位,收入份额最大,为28.46%,并得到了先进的泌尿护理基础设施、高额保健支出以及越来越多地采用膀胱功能失调治疗疗法的支持。
2025年,受广泛使用胆碱剂、膀胱放松剂以及管理泌尿和膀胱收缩紊乱症的辅助药物的驱使,药理治疗部分在市场上占据了38.74%的份额。
2026年至2033年,联合王国的CAGR市场预计将增长最快,为5.1%,而尿道疾病意识的提高、老年人口的增加以及泌尿道治疗服务投资的扩大为这一市场提供了动力。
硬细胞和基因治疗是增长最快的类型,预计CAGR为5.8%,反映出注重再生膀胱治疗方法的研究活动激增。
口服部分主导了2025年管理类别的路线,收入份额为56.21%,由慢性膀胱功能障碍管理口服药物的高处方率所带动.
神经诱发性不足的布拉德占市场的61.42%,因为脊髓损伤、帕金森病、多发性硬化症和与糖尿病有关的神经损伤等神经系统疾病发生率很高。
父母部分是行政类别增长最快的途径,CAGR为5.3%,其动力是越来越多地采用可注射神经调节剂和针对严重膀胱功能障碍病例的高级生物疗法。

市场大小和预测

全球市场价值(2025):1.15亿美元
预期市场价值(2033年):1.63亿美元
CAGR(2026-2033年):4.5%
2025年主要国家:德国
增长最快的国家:联合王国

报告范围和Europe 活动不足的Bladder 市场分割

属性	欧洲未活跃的Bladder 键市场透视
覆盖部分	按类型: 药物疗法、外科手术方法、泌尿辅助设备、化粪池和基因治疗按行政区划n: 口腔、家长和其他按疾病类型: 神经性低活性平板和无神经性低活性平板按发行频道: 医院药房、零售药房等
涵盖国家	欧洲德国法国英国。荷兰瑞士比利时 · 俄罗斯 · 意大利 • 西班牙土耳其 · 欧洲其他地区
关键市场玩家	• 妇女阿斯泰拉斯制药公司(日本) • 妇女波士顿科学公司(美国). • 妇女科洛普拉斯公司(丹麦) • 妇女召集组 PLC(吴. • 妇女厨师(美国). 霍利斯特公司(美国) B. Braun SE(德国) · 美敦尼克(爱尔兰) Teleflex公司(美国) 健康保健(瑞典) · 劳工医疗技术公司(加拿大) · 辉瑞公司(美国) • AbbVie公司(美国) · UroMems(法国) Axonics股份有限公司(美国) · C.R.Bard, Inc.(美国) * 奥林匹斯公司(日本) Fresenius医疗协会(德国) · Cogentix医疗公司(美国) · BD(美国)
市场机会	越来越多地采用圣体神经调节和可植入的膀胱刺激装置增加对再生医学和干细胞膀胱疗法的临床研究扩大家用导管产品和远程泌尿监测解决方案
添加数据信息集的值	除了对市场价值、增长率、分割、地理覆盖和主要角色等市场假设的深刻见解外,由数据桥市场研究编写的市场报告还包括深入的专家分析、病人流行病学、管道分析、定价分析和监管框架。

欧洲活跃程度低的市场趋势

趋势:逐步采用最小侵入神经调节疗法

欧洲各地的保健提供者越来越多地采用最低侵入性神经调节疗法,以改进对膀胱功能不足和慢性泌尿性留作症的长期管理。诸如圣神经刺激和可移植膀胱控制系统等技术,由于能够改善病人的结果并同时减少对长期导管的依赖,因此正在获得牵引力。医院和专门的泌尿科中心也正在整合先进的诊断监测和康复方案,以支持个性化治疗规划,而老龄化人口的认识日益提高,正在加速接受创新的膀胱功能障碍疗法。

例如,2024年3月,欧洲泌尿学协会的研究人员强调指出,在临床上越来越多地采用圣体神经调节疗法,用于欧洲多个保健中心的慢性泌尿和膀胱管理。

欧洲未活跃的市场动态

关键市场驱动力:与年龄有关和神经诱发性疾病发病率上升

欧洲各地神经系统疾病、糖尿病、脊髓损伤和与年龄有关的膀胱功能障碍的日益普遍,极大地推动了对膀胱功能不足的诊断和治疗解决方案的需求。老年人口越来越容易患上慢性泌尿道滞留症和膀胱萎缩症,鼓励医院和泌尿科诊所扩大专业护理服务。此外,诊断技术、报销政策和提高认识运动的改进正在支持早期诊断和长期疾病管理,从而促进欧洲各主要保健系统的市场持续增长。

例如,在2025年1月,国家卫生服务局扩大了专门的关节和神经神经学支助方案,旨在改善患有慢性膀胱功能障碍的老年病人获得治疗的机会。

关键限制/挑战:对未充分发挥作用的布拉德条件的认识和诊断不足

欧洲膀胱功能不足市场的一个主要制约因素是公众认识有限,与慢性膀胱功能失调有关的诊断也经常不足。症状经常与其他低尿道病症相重叠,导致临床评价延迟并降低治疗采纳率. 此外,与泌尿道疾病有关的检查做法不足和社会耻辱使患者无法及时寻求医疗。在某些欧洲国家,在获得高级空气动力学测试和专科泌尿科服务方面的可变性进一步限制了早期发现和综合疾病管理。

例如,2024年9月,欧洲骨质疏松症、骨质炎和肌肉骨骼疾病临床和经济问题学会报告说,在欧洲的几个保健系统中,老年患者的尿道疾病发病率较低,但报告率和治疗率仍然很低。

主要市场机会:再生医学和智能凯瑟特技术的扩展

再生医学和下一代智能导管技术的进步为欧洲活动不足的膀胱市场提供了巨大的增长机会. 正在进行的研究涉及干细胞疗法、生物工程组织修复和可穿戴的膀胱监测系统,这些研究有助于制定更有效的长期治疗方法。此外,增加对连通的保健平台和以家庭为基础的病人管理解决方案的投资,使整个欧洲的老年人和受行动限制的人口能够持续监测和个性化地提供护理。

例如,2024年6月,科洛普拉斯特宣布扩大投资,以欧洲长期泌尿和膀胱功能失调管理为目标,开发先进的相关护理技术和数字患者支持解决方案。

欧洲未活跃的市场范围

欧洲活动不足的膀胱市场根据类型、管理途径、疾病类型和分配渠道进行分化。

按类型

根据类型,欧洲活性不足的膀胱市场被分入药理疗法,外科手术方法,尿道辅助装置,干细胞和基因疗法. 2025年,由于广泛使用胆碱剂、膀胱放松剂以及用于管理泌尿和膀胱收缩紊乱的辅助药物,药理治疗部分占了市场的38.74%。这些疗法通常被开具一线治疗的处方,因为这些疗法是非侵入性的,而且各医院和门诊部可广泛使用。与年龄有关的膀胱功能障碍和神经致病性膀胱功能障碍的诊断越来越多,这支持了对长期药理管理的需求。医生还倾向于为不适合手术或入侵手术的老年病人提供药物治疗。在整个欧洲保健系统中提供优惠的报销支助和大量非专利药品,继续加强部分增长。然而,在严重的活性不足的膀胱条件下,长期疗效有限仍然是这一部分的临床挑战.

预计Stem细胞和基因治疗部分在2026年至2033年的CAGR增长最快,为5.8%,其动力是越来越多的研究活动侧重于再生膀胱治疗方法。这些先进的疗法旨在通过细胞再生和有针对性的基因干预来恢复膀胱肌肉功能和神经信号. 越来越多的精密医学和再生泌尿道投资正在支持整个欧洲开发创新性临床阶段疗法。学术机构和生物技术公司日益合作加快治疗商业化。除了导管和症状管理外,对长期治疗性替代品的需求日益增加,这进一步推动了市场的扩大。此外,组织工程和个性化医学方面的有利进展预计将为这一部分的未来创造出强劲的机会。

按行政路线分列

根据管理路线,欧洲活性不足的膀胱市场分为口服,亲服等. 由于慢性膀胱功能障碍管理口服药的开处方率高,2025年口服部分占市场主导份额为56.21%. 口服治疗比注射疗法更方便、更方便、更便于遵守,而且成本效益更高,特别是在需要长期治疗的老年人中。保健提供者普遍倾向于口服药物进行初步疾病管理,因为这些药物很容易融入门诊护理环境。多种品牌和通用治疗方法的提供也支持了整个欧洲的分块增长。此外,口服药物减少了对医院探访和程序干预的需求,改善了老年人口获得治疗的机会。通过零售和医院药店大力分销,进一步助长了这一部门的支配地位。

父母部分预计将在2026年至2033年达到5.3%的CAGR增长最快,其动力是越来越多地采用可注射神经调节剂和针对严重膀胱功能障碍病例的高级生物疗法。父母的治疗能够更快地采取治疗行动,提高药物的生物利用率,使之适合神经致病性膀胱功能障碍的患者。医院和专科泌尿科中心越来越多地使用可注射疗法,同时采用最低侵入性治疗程序。再生医学研究和生物制品开发的增长进一步支撑了分块扩张. 此外,对有针对性的疗法和专门的膀胱康复方案越来越偏好,这加速了对高级注射治疗办法的需求。增加涉及新生物化合物的临床试验预计也会加强长期增长前景。

按疾病类型

根据疾病类型,欧洲活性不足的膀胱市场被分出为神经源活性不足的膀胱和无神经源活性不足的膀胱. 在脊髓损伤、帕金森病、多发性硬化症和与糖尿病有关的神经损伤等神经系统紊乱的高发率的推动下,2025年神经诱发性低活性血球板部分以61.42%的比重主导了市场。神经致病性膀胱功能障碍的患者往往需要长期的导管化,神经调节疗法,以及持续的泌尿道监测等,有助于更高的治疗需求. 在欧洲各地,老年人口的增加和慢性神经病的发生率的上升进一步支撑了部分的增长。保健提供者也在扩大获得神经致尿性疾病高级诊断检测和康复方案的机会。大力采用最低侵入性疗法和专门护理服务继续强化了这一阶层的主导地位。此外,对神经-泌尿管理的认识不断提高,有助于早期诊断和治疗。

2026至2033年,由于对与神经系统疾病无关的与年龄有关的膀胱功能障碍和慢性泌尿障碍的诊断增加,非神经诱发性低活性血浆分泌率增长最快,为5.0%。人们对小便道症状的认识不断提高并扩大了接受专门泌尿道护理的机会,这有助于提高整个欧洲的疾病检测率。保健提供者越来越多地对非神经性膀胱病采用最低侵入性治疗办法和先进的诊断技术。此外,与生活方式有关的风险因素、骨盆底部失调和外科膀胱后并发症正在助长分块扩张。越来越多的康复方案和门诊膀胱管理服务也在加速治疗的采用。越来越注重早期干预和个性化的病人护理,将进一步支持长期分块增长。

按发行频道

根据分销渠道,欧洲活动不足的膀胱市场分为医院药房,零售药房等. 2025年,由于大量处方药、导管产品和专科膀胱管理疗法通过医院网络分发,医院药房部分在市场上占有47.18%的份额。医院药房在支持住院和门诊泌尿治疗方案方面发挥着关键作用,特别是针对需要持续临床监测的老年和神经性膀胱病人。提供专门的处方产品和报销支持的疗法,进一步助长了局部优势。此外,医院在医生、药剂师和护理专家之间保持强有力的协调,以确保优化治疗管理。越来越多的先进注射疗法和神经调节相关药物的采用也日益依赖医院的药房分配。与全欧洲公共保健系统的强有力融合继续支持市场领导。

由于对可获得的长期膀胱管理药物和家庭相关护理产品的需求增加,零售药房部分预计将在2026年至2033年达到5.2%的CAGR增长最快。零售药店为在医院外管理慢性泌尿障碍的病人提供方便的处方补药、导管用品和支持性膀胱护理产品。社区药房服务和数字处方平台的扩大正在进一步改善整个欧洲的治疗便利。老年人越来越倾向于门诊护理和家庭保健管理,这正在加速部分增长。此外,药剂师越来越多地参与与泌尿功能障碍有关的病人咨询和慢性病管理方案。在线药房服务和家用用品的供应日益增加,也支持这一部门的迅速扩展。

欧洲未活跃的布拉德市场区域分析

2025年,德国在欧洲的膀胱不活跃市场占据了主导地位,收入份额最大,为28.46%,并得到了先进的泌尿护理基础设施、高额保健支出以及越来越多地采用膀胱功能失调治疗疗法的支持。该国还受益于慢性泌尿功能障碍诊断率的提高,大量采用最低侵入性神经调节疗法,以及越来越多的专科膀胱功能障碍治疗中心。老年人口不断增加,临床研究活动扩大,医院和泌尿科诊所越来越多地使用先进的诊断技术,这些继续加强了德国在欧洲膀胱不足市场的领导地位。

德国未活跃的布拉德市场透视

德国的膀胱功能不足市场正在稳步增长,原因是慢性泌尿道留滞症发病率上升,保健基础设施先进,以及越来越多地采用侵入性最小的膀胱功能障碍疗法。该国强大的泌尿护理网络,以及越来越多的使用神经调节装置、导管管理解决方案和先进的诊断技术,正在推动医院和专科诊所的需求。此外,越来越多的老年人口和对低尿道障碍的认识正在加速治疗的采用和支持整个德国的长期市场扩张。

英国未活跃的Bladder 市场透视

英国活动不足的膀胱市场正在稳步增长,对泌尿道留滞症的认识得到提高,保健支出增加,并且越来越多地采用最低侵入性治疗程序。扩大提供连续护理方案和专门的神经-泌尿科服务有助于各医院和门诊护理中心的市场发展。此外,先进的诊断成像、膀胱监测技术和康复方案的结合正在改善治疗结果,并使英国成为膀胱功能失调管理解决方案的关键市场。

法国未活跃的布拉德市场透视

法国的膀胱功能不足市场正在稳步扩大,原因是该国建立了完善的保健基础设施,增加了对神经性膀胱病的诊断,对长期护理解决方案的需求也越来越大。医院和泌尿科诊所越来越多地采用先进的导管系统、药理疗法和膀胱康复方案来改善病人的护理。在最低侵入性程序方面不断取得进展并增加对泌尿科研究的投资,加上政府强有力的保健支助,进一步推动了法国的市场增长。

意大利未活跃的布拉德市场透视

意大利的膀胱功能不足市场由于人口老化、慢性泌尿功能障碍发病率上升以及扩大获得专门泌尿护理服务的机会而出现显著增长。保健提供者越来越多地利用先进的诊断技术、以导管为基础的管理系统和神经调节疗法来改善膀胱功能障碍患者的治疗结果。此外,人们日益认识到相关护理问题,并增加了保健投资,支持意大利各医院和康复中心采用创新膀胱管理办法。

欧洲未活跃的布拉德市场份额

欧洲活动不足的膀胱产业主要由历史悠久的公司领导,其中包括:

Astellas Pharma Inc.(日本)
波士顿科学公司(美国)
科洛普拉斯公司(丹麦)
Contratic Group PLC (英国).
库克 (美国).
霍利斯特公司(美国)
布劳恩·塞(德国)
梅德罗尼克(爱尔兰)
Teleflex公司(美国)
健康护理(瑞典)
Laborie医疗技术公司(加拿大)
辉瑞股份有限公司(美国)
AbbVie Inc. (美国).
乌罗梅斯(法国)
Axonics股份有限公司(美国)
R. Bard, Inc. (美国)
奥林匹斯公司(日本)
Fresenius Medical Care AG(德国)
Cogentix医疗股份有限公司(美国)
BD (美国).

欧洲最新事态发展

2025年8月,Coloplast报告说,在欧洲,由于大量采用LujaTM和SpeciCath®导管溶液用于慢性泌尿和膀胱功能失调管理,其相关护理业务正在扩大。该公司还注意到,在若干欧洲保健市场,报销支助不断增加,家庭护理产品也日益被采用。
2025年5月,Coloplast宣布通过将LujaTM产品更广泛地商业化,供男女用户使用,进一步扩大其在欧洲各地的连续护理组合。该公司指出,欧洲市场的增长,特别是英国、法国和德国的增长,是由于越来越多地采用先进的间歇导管技术进行慢性膀胱功能失调管理。
2025年2月,科洛普拉斯特报告说,在Q1 2024/25期间,由于LujaTM导管技术在欧洲市场的扩展,其闭塞护理部分继续增长. 该公司强调,泌尿障碍和由神经引起的膀胱失调患者对先进的膀胱空出解决方案和以家庭为基础的结肠管理产品的需求日益增加。
2024年11月,科洛普拉斯宣布其全欧洲的Continence Care业务强劲增长,并越来越多地采用LujaTM间歇导管平台和Peristeen' 加上肠道护理解决方案. 该公司报告说,法国和英国等国对高级节能和膀胱管理产品的需求不断增长,这反映出对慢性泌尿功能障碍的治疗正在扩大。
2024年4月,欧洲泌尿学协会发表了更新的临床指导并发表总结论文,重点阐述活性不足的膀胱管理和非神经性低尿道症状. 该出版物强调越来越重视早期诊断、改进了空气动力学测试和慢性泌尿道留滞症的个性化治疗方法。最新建议可望支持在欧洲保健系统更广泛地采用先进的诊断和治疗技术。

SKU-69094

在线获取全球首个市场情报云平台的报告访问权限

点击图片放大

交互式数据分析仪表板
用于发现高增长潜力机会的公司分析仪表板
研究分析师支持（定制与咨询）
带有交互式仪表板的竞争对手分析
最新新闻、更新与趋势分析
利用基准分析的强大功能，实现全面的竞争对手跟踪

申请演示

表格列表

TABLE 1 TOTAL 40 DOXAZOSIN DRUGS WERE DISCONTINUED FROM THE MARKET

TABLE 2 TOTAL 38 DOXAZOSIN DRUGS ARE STILL IN THE MARKET

TABLE 3 TOTAL PRESCRIPTION AND DISCONTINUED DRUGS (DOXAZOSIN) BY COMPANY

TABLE 4 TOTAL 58 DRUGS DISCONTINUED

TABLE 5 TOTAL PRESCRIPTION AND DISCONTINUED DRUGS (BETHANECHOL CHLORIDE) BY COMPANY

TABLE 6 OUT OF 3,128 STUDIES ON BLADDER DISORDER, ONLY 22 STUDIES ARE ONGOING FOR THE UAB-

TABLE 7 THESE CLINICAL TRIALS ARE MOSTLY RECRUITING/ONGOING IN DIFFERENT REGIONS OF THE WORLD-

TABLE 8 TOP ACQUISITIONS OF 2021 RANKED BY TOTAL DEAL VALUE:

TABLE 9 FDA REQUIRES THE FOLLOWING SCENARIO BEFORE A DRUG IS APPROVED

TABLE 10 EUROPE UNDERACTIVE BLADDER MARKET, TYPE, 2020-2029 (USD MILLION)

TABLE 11 EUROPE PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 12 EUROPE PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 13 EUROPE PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 14 EUROPE BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 15 EUROPE BY PRODUCT TYPE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 16 EUROPE BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 17 EUROPE SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 18 EUROPE SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 19 EUROPE URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 20 EUROPE URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 21 EUROPE STEM CELL AND GENE THERAPIES IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 22 EUROPE STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 23 EUROPE UNDERACTIVE BLADDER MARKET , BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 24 EUROPE PARENTERAL IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 25 EUROPE ORAL IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 26 EUROPE OTHERS IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 27 EUROPE UNDERACTIVE BLADDER MARKET , BY END USER, 2020-2029 (USD MILLION)

TABLE 28 EUROPE HOSPITALS IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 29 EUROPE CLINICS IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 30 EUROPE ACADEMIC AND RESEARCH IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 31 EUROPE OTHERS IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 32 EUROPE UNDERACTIVE BLADDER MARKET , BY DISTRIBUTION CHANNEL , 2020-2029 (USD MILLION)

TABLE 33 EUROPE HOSPITAL PHARMACY IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 34 EUROPE RETAIL PHARMACY IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 35 EUROPE OTHERS IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 36 EUROPE UNDERACTIVE BLADDER MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 37 EUROPE UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 38 EUROPE PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 39 EUROPE PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 40 EUROPE BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 41 EUROPE BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)

TABLE 42 EUROPE BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (ASP)

TABLE 43 EUROPE BY PRODUCT TYPE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 44 EUROPE BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 45 EUROPE BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)

TABLE 46 EUROPE BRANDED TYPES IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 47 EUROPE SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 48 EUROPE URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 49 EUROPE STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 50 EUROPE UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020- 2029 (USD MILLION)

TABLE 51 EUROPE UNDERACTIVE BLADDER MARKET, BY END USER, 2020- 2029 (USD MILLION)

TABLE 52 EUROPE UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)

TABLE 53 GERMANY UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 54 GERMANY PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 55 GERMANY PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 56 GERMANY BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 57 GERMANY BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)

TABLE 58 GERMANY BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (ASP)

TABLE 59 GERMANY BY PRODUCT TYPE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 60 GERMANY BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 61 GERMANY BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)

TABLE 62 GERMANY BRANDED TYPES IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 63 GERMANY SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 64 GERMANY URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 65 GERMANY STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 66 GERMANY UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020- 2029 (USD MILLION)

TABLE 67 GERMANY UNDERACTIVE BLADDER MARKET, BY END USER, 2020- 2029 (USD MILLION)

TABLE 68 GERMANY UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)

TABLE 69 FRANCE UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 70 FRANCE PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 71 FRANCE PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 72 FRANCE BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 73 FRANCE BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)

TABLE 74 FRANCE BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (ASP)

TABLE 75 FRANCE BY PRODUCT TYPE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 76 FRANCE BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 77 FRANCE BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)

TABLE 78 FRANCE BRANDED TYPES IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 79 FRANCE SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 80 FRANCE URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 81 FRANCE STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 82 FRANCE UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020- 2029 (USD MILLION)

TABLE 83 FRANCE UNDERACTIVE BLADDER MARKET, BY END USER, 2020- 2029 (USD MILLION)

TABLE 84 FRANCE UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)

TABLE 85 U.K. UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 86 U.K. PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 87 U.K. PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 88 U.K. BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 89 U.K. BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)

TABLE 90 U.K. BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (ASP)

TABLE 91 U.K. BY PRODUCT TYPE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 92 U.K. BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 93 U.K. BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)

TABLE 94 U.K. BRANDED TYPES IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 95 U.K. SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 96 U.K. URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 97 U.K. STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 98 U.K. UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020- 2029 (USD MILLION)

TABLE 99 U.K. UNDERACTIVE BLADDER MARKET, BY END USER, 2020- 2029 (USD MILLION)

TABLE 100 U.K. UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)

TABLE 101 ITALY UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 102 ITALY PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 103 ITALY PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 104 ITALY BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 105 ITALY BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)

TABLE 106 ITALY BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (ASP)

TABLE 107 ITALY BY PRODUCT TYPE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 108 ITALY BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 109 ITALY BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)

TABLE 110 ITALY BRANDED TYPES IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 111 ITALY SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 112 ITALY URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 113 ITALY STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 114 ITALY UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020- 2029 (USD MILLION)

TABLE 115 ITALY UNDERACTIVE BLADDER MARKET, BY END USER, 2020- 2029 (USD MILLION)

TABLE 116 ITALY UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)

TABLE 117 RUSSIA UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 118 RUSSIA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 119 RUSSIA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 120 RUSSIA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 121 RUSSIA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)

TABLE 122 RUSSIA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (ASP)

TABLE 123 RUSSIA BY PRODUCT TYPE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 124 RUSSIA BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 125 RUSSIA BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)

TABLE 126 RUSSIA BRANDED TYPES IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 127 RUSSIA SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 128 RUSSIA URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 129 RUSSIA STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 130 RUSSIA UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020- 2029 (USD MILLION)

TABLE 131 RUSSIA UNDERACTIVE BLADDER MARKET, BY END USER, 2020- 2029 (USD MILLION)

TABLE 132 RUSSIA UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)

TABLE 133 SPAIN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 134 SPAIN PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 135 SPAIN PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 136 SPAIN BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 137 SPAIN BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)

TABLE 138 SPAIN BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (ASP)

TABLE 139 SPAIN BY PRODUCT TYPE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 140 SPAIN BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 141 SPAIN BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)

TABLE 142 SPAIN BRANDED TYPES IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 143 SPAIN SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 144 SPAIN URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 145 SPAIN STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 146 SPAIN UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020- 2029 (USD MILLION)

TABLE 147 SPAIN UNDERACTIVE BLADDER MARKET, BY END USER, 2020- 2029 (USD MILLION)

TABLE 148 SPAIN UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)

TABLE 149 TURKEY UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 150 TURKEY PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 151 TURKEY PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 152 TURKEY BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 153 TURKEY BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)

TABLE 154 TURKEY BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (ASP)

TABLE 155 TURKEY BY PRODUCT TYPE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 156 TURKEY BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 157 TURKEY BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)

TABLE 158 TURKEY BRANDED TYPES IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 159 TURKEY SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 160 TURKEY URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 161 TURKEY STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 162 TURKEY UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020- 2029 (USD MILLION)

TABLE 163 TURKEY UNDERACTIVE BLADDER MARKET, BY END USER, 2020- 2029 (USD MILLION)

TABLE 164 TURKEY UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)

TABLE 165 NETHERLANDS UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 166 NETHERLANDS PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 167 NETHERLANDS PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 168 NETHERLANDS BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 169 NETHERLANDS BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)

TABLE 170 NETHERLANDS BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (ASP)

TABLE 171 NETHERLANDS BY PRODUCT TYPE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 172 NETHERLANDS BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 173 NETHERLANDS BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)

TABLE 174 NETHERLANDS BRANDED TYPES IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 175 NETHERLANDS SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 176 NETHERLANDS URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 177 NETHERLANDS STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 178 NETHERLANDS UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020- 2029 (USD MILLION)

TABLE 179 NETHERLANDS UNDERACTIVE BLADDER MARKET, BY END USER, 2020- 2029 (USD MILLION)

TABLE 180 NETHERLANDS UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)

TABLE 181 SWITZERLAND UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 182 SWITZERLAND PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 183 SWITZERLAND PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 184 SWITZERLAND BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 185 SWITZERLAND BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)

TABLE 186 SWITZERLAND BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (ASP)

TABLE 187 SWITZERLAND BY PRODUCT TYPE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 188 SWITZERLAND BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 189 SWITZERLAND BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)

TABLE 190 SWITZERLAND BRANDED TYPES IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 191 SWITZERLAND SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 192 SWITZERLAND URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 193 SWITZERLAND STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 194 SWITZERLAND UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020- 2029 (USD MILLION)

TABLE 195 SWITZERLAND UNDERACTIVE BLADDER MARKET, BY END USER, 2020- 2029 (USD MILLION)

TABLE 196 SWITZERLAND UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)

TABLE 197 POLAND UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 198 POLAND PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 199 POLAND PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 200 POLAND BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 201 POLAND BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)

TABLE 202 POLAND BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (ASP)

TABLE 203 POLAND BY PRODUCT TYPE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 204 POLAND BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 205 POLAND BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)

TABLE 206 POLAND BRANDED TYPES IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 207 POLAND SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 208 POLAND URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 209 POLAND STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 210 POLAND UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020- 2029 (USD MILLION)

TABLE 211 POLAND UNDERACTIVE BLADDER MARKET, BY END USER, 2020- 2029 (USD MILLION)

TABLE 212 POLAND UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)

TABLE 213 AUSTRIA UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 214 AUSTRIA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 215 AUSTRIA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 216 AUSTRIA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 217 AUSTRIA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)

TABLE 218 AUSTRIA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (ASP)

TABLE 219 AUSTRIA BY PRODUCT TYPE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 220 AUSTRIA BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 221 AUSTRIA BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)

TABLE 222 AUSTRIA BRANDED TYPES IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 223 AUSTRIA SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 224 AUSTRIA URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 225 AUSTRIA STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 226 AUSTRIA UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020- 2029 (USD MILLION)

TABLE 227 AUSTRIA UNDERACTIVE BLADDER MARKET, BY END USER, 2020- 2029 (USD MILLION)

TABLE 228 AUSTRIA UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)

TABLE 229 HUNGARY UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 230 HUNGARY PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 231 HUNGARY PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 232 HUNGARY BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 233 HUNGARY BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)

TABLE 234 HUNGARY BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (ASP)

TABLE 235 HUNGARY BY PRODUCT TYPE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 236 HUNGARY BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 237 HUNGARY BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)

TABLE 238 HUNGARY BRANDED TYPES IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 239 HUNGARY SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 240 HUNGARY URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 241 HUNGARY STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 242 HUNGARY UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020- 2029 (USD MILLION)

TABLE 243 HUNGARY UNDERACTIVE BLADDER MARKET, BY END USER, 2020- 2029 (USD MILLION)

TABLE 244 HUNGARY UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)

TABLE 245 NORWAY UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 246 NORWAY PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 247 NORWAY PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 248 NORWAY BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 249 NORWAY BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)

TABLE 250 NORWAY BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (ASP)

TABLE 251 NORWAY BY PRODUCT TYPE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 252 NORWAY BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 253 NORWAY BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)

TABLE 254 NORWAY BRANDED TYPES IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 255 NORWAY SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 256 NORWAY URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 257 NORWAY STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 258 NORWAY UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020- 2029 (USD MILLION)

TABLE 259 NORWAY UNDERACTIVE BLADDER MARKET, BY END USER, 2020- 2029 (USD MILLION)

TABLE 260 NORWAY UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)

TABLE 261 IRELAND UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 262 IRELAND PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 263 IRELAND PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 264 IRELAND BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 265 IRELAND BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)

TABLE 266 IRELAND BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (ASP)

TABLE 267 IRELAND BY PRODUCT TYPE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 268 IRELAND BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 269 IRELAND BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)

TABLE 270 IRELAND BRANDED TYPES IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 271 IRELAND SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 272 IRELAND URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 273 IRELAND STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 274 IRELAND UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020- 2029 (USD MILLION)

TABLE 275 IRELAND UNDERACTIVE BLADDER MARKET, BY END USER, 2020- 2029 (USD MILLION)

TABLE 276 IRELAND UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)

TABLE 277 LITHUANIA UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 278 LITHUANIA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 279 LITHUANIA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 280 LITHUANIA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 281 LITHUANIA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)

TABLE 282 LITHUANIA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (ASP)

TABLE 283 LITHUANIA BY PRODUCT TYPE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 284 LITHUANIA BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 285 LITHUANIA BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)

TABLE 286 LITHUANIA BRANDED TYPES IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 287 LITHUANIA SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 288 LITHUANIA URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 289 LITHUANIA STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 290 LITHUANIA UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020- 2029 (USD MILLION)

TABLE 291 LITHUANIA UNDERACTIVE BLADDER MARKET, BY END USER, 2020- 2029 (USD MILLION)

TABLE 292 LITHUANIA UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)

TABLE 293 REST OF EUROPE UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

图片列表

FIGURE 1 EUROPE UNDERACTIVE BLADDER MARKET: SEGMENTATION

FIGURE 2 EUROPE UNDERACTIVE BLADDER MARKET: DATA TRIANGULATION

FIGURE 3 EUROPE UNDERACTIVE BLADDER MARKET: DROC ANALYSIS

FIGURE 4 EUROPE UNDERACTIVE BLADDER MARKET: EUROPE VS REGIONAL MARKET ANALYSIS

FIGURE 5 EUROPE UNDERACTIVE BLADDER MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 EUROPE UNDERACTIVE BLADDER MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 EUROPE UNDERACTIVE BLADDER MARKET: DBMR MARKET POSITION GRID

FIGURE 8 EUROPE UNDERACTIVE BLADDER MARKET: MARKET APPLICATION COVERAGE GRID

FIGURE 9 EUROPE UNDERACTIVE BLADDER MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 EUROPE UNDERACTIVE BLADDER MARKET: SEGMENTATION

FIGURE 11 INCREASING PREVALENCE OF NEUROGENIC BLADDER INFECTIONS IS EXPECTED TO DRIVE THE EUROPE UNDERACTIVE BLADDER MARKET IN THE FORECAST PERIOD

FIGURE 12 TREATMENT SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE UNDERACTIVE BLADDER MARKET IN 2022 & 2029

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF EUROPE UNDERACTIVE BLADDER MARKET

FIGURE 14 EUROPE UNDERACTIVE BLADDER MARKET : TYPE, 2021

FIGURE 15 EUROPE UNDERACTIVE BLADDER MARKET : TYPE, 2022-2029 (USD MILLION)

FIGURE 16 EUROPE UNDERACTIVE BLADDER MARKET : TYPE, CAGR (2022-2029)

FIGURE 17 EUROPE UNDERACTIVE BLADDER MARKET : TYPE, LIFELINE CURVE

FIGURE 18 EUROPE UNDERACTIVE BLADDER MARKET : BY ROUTE OF ADMINISTRATION, 2021

FIGURE 19 EUROPE UNDERACTIVE BLADDER MARKET : BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)

FIGURE 20 EUROPE UNDERACTIVE BLADDER MARKET : BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)

FIGURE 21 EUROPE UNDERACTIVE BLADDER MARKET : BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 22 EUROPE UNDERACTIVE BLADDER MARKET : BY END USER, 2021

FIGURE 23 EUROPE UNDERACTIVE BLADDER MARKET : BY END USER, 2022-2029 (USD MILLION)

FIGURE 24 EUROPE UNDERACTIVE BLADDER MARKET : BY END USER, CAGR (2022-2029)

FIGURE 25 EUROPE UNDERACTIVE BLADDER MARKET : BY END USER, LIFELINE CURVE

FIGURE 26 EUROPE UNDERACTIVE BLADDER MARKET : BY DISTRIBUTION CHANNEL, 2021

FIGURE 27 EUROPE UNDERACTIVE BLADDER MARKET : BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)

FIGURE 28 EUROPE UNDERACTIVE BLADDER MARKET : BY DISTRIBUTION CHANNEL, CAGR (2022-2029)

FIGURE 29 EUROPE UNDERACTIVE BLADDER MARKET : BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 30 EUROPE UNDERACTIVE BLADDER MARKET: SNAPSHOT (2021)

FIGURE 31 EUROPE UNDERACTIVE BLADDER MARKET: BY COUNTRY (2021)

FIGURE 32 EUROPE UNDERACTIVE BLADDER MARKET: BY COUNTRY (2022 & 2029)

FIGURE 33 EUROPE UNDERACTIVE BLADDER MARKET: BY COUNTRY (2021 & 2029)

FIGURE 34 EUROPE UNDERACTIVE BLADDER MARKET: BY TYPE (2022-2029)

FIGURE 35 EUROPE UNDERACTIVE BLADDER MARKET: COMPANY SHARE 2021 (%)

查看详细信息

研究方法

数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。该阶段包括通过各种来源和策略获取市场信息或相关数据。它包括提前检查和规划从过去获得的所有数据。它同样包括检查不同信息源中出现的信息不一致。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。要了解更多信息，请请求分析师致电或下拉您的询问。

DBMR 研究团队使用的关键研究方法是数据三角测量，其中包括数据挖掘、数据变量对市场影响的分析和主要（行业专家）验证。数据模型包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、专利分析、定价分析、公司市场份额分析、测量标准、全球与区域和供应商份额分析。要了解有关研究方法的更多信息，请向我们的行业专家咨询。

可定制

Data Bridge Market Research 是高级形成性研究领域的领导者。我们为向现有和新客户提供符合其目标的数据和分析而感到自豪。报告可定制，包括目标品牌的价格趋势分析、了解其他国家的市场（索取国家列表）、临床试验结果数据、文献综述、翻新市场和产品基础分析。目标竞争对手的市场分析可以从基于技术的分析到市场组合策略进行分析。我们可以按照您所需的格式和数据样式添加您需要的任意数量的竞争对手数据。我们的分析师团队还可以为您提供原始 Excel 文件数据透视表（事实手册）中的数据，或者可以帮助您根据报告中的数据集创建演示文稿。

常见问题

市场的增长率是多少?

根据预测,欧洲未活跃的布拉德市场将以4.5%的CAGR增长。

谁是在市场上经营的主要角色?

在欧洲未活跃的Bladder市场运营的主要角色有:Astellas Pharma Inc.,Aurobindo Pharma.,Boehringer Ingelheim International GmbH,Macleods 制药有限公司,猎户座公司,ONO PHARMACEUTICAL CO.,LTD.,诺瓦尔蒂斯AG,辉瑞公司,Reddy博士实验室有限公司,Teva制药工业有限公司,太阳制药工业有限公司,Almirall,S.A.,Glenwood,Vesiflo, Inc.,和Alkem Labs. 还有其他。

什么是类型段?

根据类型,欧洲低活性Bladder市场被分入了药用疗法,外科方法,尿道辅助装置,以及Stem Cell和基因疗法.

市场覆盖的主要国家是什么?

欧洲未活跃的布拉德市场覆盖的主要国家有:德国,法国,英国,意大利,俄罗斯,西班牙,土耳其,荷兰,瑞士,波兰,土耳其,奥地利,匈牙利,挪威,爱尔兰,卢森堡,立陶宛等欧洲其他地区.

欧洲膀胱市场目前的规模是多少?

欧洲未活跃的膀胱市场在2025年价值为15亿美元,预计到2033年将达到16.3亿美元,从2026年到2033年CAGR增长4.5%.

欧洲膀胱不足市场的预期增长率是多少?

在2026至2033年的预测期间,欧洲的膀胱功能不足市场预计将以4.5%的CAGR增长,其动力是老年人口尿道保留障碍的流行率不断上升,对尿道功能障碍的认识不断提高,泌尿诊断和治疗技术也有所进步。

欧洲的膀胱不足市场由哪个国家主导?

2025年,德国在欧洲的膀胱不活跃市场占据了主导地位,收入份额最大,为28.46%,并得到了先进的泌尿护理基础设施、高额保健支出以及越来越多地采用膀胱功能失调治疗疗法的支持。

哪个国家是欧洲低活性膀胱市场增长最快的国家?

2026年至2033年,联合王国的CAGR市场预计将增长最快,为5.1%,而尿道疾病意识的提高、老年人口的增加以及泌尿道治疗服务投资的扩大为这一市场提供了动力。

欧洲未活跃的市场规模、份额和趋势分析报告——2033年工业概况和预测